Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.

Klumpers LE, Roy C, Ferron G, Turpault S, Poitiers F, Pinquier JL, van Hasselt JG, Zuurman L, Erwich FA, van Gerven JM.

Br J Clin Pharmacol. 2013 Jul;76(1):65-77. doi: 10.1111/bcp.12071.

2.

Behavioral effects of cannabinoid agents in animals.

Chaperon F, Thiébot MH.

Crit Rev Neurobiol. 1999;13(3):243-81. Review.

PMID:
10803637
3.

Synaptic targets of Δ9-tetrahydrocannabinol in the central nervous system.

Hoffman AF, Lupica CR.

Cold Spring Harb Perspect Med. 2013 Aug 1;3(8). pii: a012237. doi: 10.1101/cshperspect.a012237. Review.

4.

Biomarkers for the effects of cannabis and THC in healthy volunteers.

Zuurman L, Ippel AE, Moin E, van Gerven JM.

Br J Clin Pharmacol. 2009 Jan;67(1):5-21. doi: 10.1111/j.1365-2125.2008.03329.x. Review.

5.

A role for cannabinoid CB1 receptors in mood and anxiety disorders.

Witkin JM, Tzavara ET, Nomikos GG.

Behav Pharmacol. 2005 Sep;16(5-6):315-31. Review.

PMID:
16148437
6.

[Neurobiology of endocannabinoids and central effects of tetrahydrocannabinol contained in indian hemp].

Costentin J.

Bull Acad Natl Med. 2014 Mar;198(3):527-38; discussion 538-9. Review. French.

PMID:
26427295
7.

Cannabinoid receptor antagonists and the metabolic syndrome: Novel promising therapeutical approaches.

Cervino C, Pasquali R, Pagotto U.

Mini Rev Med Chem. 2007 Jan;7(1):21-30. Review.

PMID:
17266634
8.

Screening Medications for the Treatment of Cannabis Use Disorder.

Panlilio LV, Justinova Z, Trigo JM, Le Foll B.

Int Rev Neurobiol. 2016;126:87-120. doi: 10.1016/bs.irn.2016.02.005. Epub 2016 Mar 10. Review.

Supplemental Content

Support Center